Haq, Afzal Asif
Interstitial cystitis-critical assessment of current treatment and opportunities for nanodelivery - Vol.56(3), Jul-Sep - Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022 - 636-645p.
The characteristic feature of Interstitial cystitis (IC) or bladder pain syndrome is augmented,
pressure, or inconvenience in the suprapubic or bladder region. The causative factors for
IC are not completely understood however certain underlying disease condition may
trigger the pain. The therapy is aimed to provide symptomatic relief, and therefore, the
treatment protocols have been established based on experience. Intravesical delivery of
drugs has been well explored and found to be most effective in minimizing the symptoms
of IC without systemic adverse events. However, the efficacy of drug absorption is
limited by the bladder wall permeability and poor absorption of the instilled drugs. The
intravesical approach should be coupled with novel nanocarriers such as nanoparticles
or liposomes to overcome these limitations. Nanoparticles can easily cross the bladder
permeability barrier and enhance the drug retention time in the bladder, making the delivery
efficient and promising. This review addresses the current IC management strategies,
new potential therapeutic agents of natural origin, and various drugs undergoing clinical
trials by different routes of administration.
PHARMACEUTICS
Interstitial cystitis-critical assessment of current treatment and opportunities for nanodelivery - Vol.56(3), Jul-Sep - Karnataka Association of Pharmaceutical Teachers of India (APTI) 2022 - 636-645p.
The characteristic feature of Interstitial cystitis (IC) or bladder pain syndrome is augmented,
pressure, or inconvenience in the suprapubic or bladder region. The causative factors for
IC are not completely understood however certain underlying disease condition may
trigger the pain. The therapy is aimed to provide symptomatic relief, and therefore, the
treatment protocols have been established based on experience. Intravesical delivery of
drugs has been well explored and found to be most effective in minimizing the symptoms
of IC without systemic adverse events. However, the efficacy of drug absorption is
limited by the bladder wall permeability and poor absorption of the instilled drugs. The
intravesical approach should be coupled with novel nanocarriers such as nanoparticles
or liposomes to overcome these limitations. Nanoparticles can easily cross the bladder
permeability barrier and enhance the drug retention time in the bladder, making the delivery
efficient and promising. This review addresses the current IC management strategies,
new potential therapeutic agents of natural origin, and various drugs undergoing clinical
trials by different routes of administration.
PHARMACEUTICS